REOLYSIN® is a formulation of human reovirus type 3 Dearing (T3D) which is being developed by Oncolytics Biotech Inc. for a number of cancer indications including pancreatic ductal adenocarcinoma (PDAC) (see here). It has entered clinical trials for pancreatic cancer in combination with a number of drugs including standard chemotherapeutics and newer immune checkpoint targeting antibodies (Pembrolizumab: trade name KEYTRUDA®) (See table 1).
Update of NCT01280058 (NCI-8601) trial based on data collected up to January 19, 2016 from the NCI
The overall survival rate was increased. A proportion of patients receiving REOLYSIN® were alive beyond three years, whereas no patients in the control group survived beyond one year.
Final results from Oncolytics Biotech Inc.’s NCT00998322 (REO 017) Phase II study
Overall survival rates were increased and the immune checkpoint protein PD-L1 was demonstrated to be increased in post-treatment tumours. This formed a rationale for the use of Pembrolizumab (KEYTRUDA®) in the new NCT02620423 (REO 024) trial.